dual glp-1/gip receptor agonists Potential Use of GLP-1 and GIP/GLP-1 for Respiratory Disorders: Where Are We at? This review summarizes how GLP-1

The risk of worsening heart failure events alone dropped by 46% (HR 0.54)

Evidence-based autoimmune disease treatments include disease-modifying antirheumatic drugs (DMARDs) like methotrexate, biologic agents targeting specific inflammatory pathways (TNF- inhibitors, IL-6 inhibitors), JAK inhibitors, corticosteroids for acute flares, and immunomodulators

Strategic Imperatives in a Shifting GLP-1 Market The GLP-1 market has exposed how quickly alternative channels like telehealth platforms and compounding pharmacies can scale and disrupt traditional brand management

Christina Dunbar Matos

Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion

10 , e020237 (2021)